Comments

Response to “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”

Dana-Farber Cancer Institute, Boston, MA
Haematologica Early view Nov 18, 2021 https://doi.org/10.3324/haematol.2021.280310